Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Questions raised over clinical value of Sanofi's semuloparin ahead of US FDA committee meeting

This article was originally published in Scrip

Executive Summary

The staff of the US FDA has presented an extremely negative view of the bid by Sanofi-Aventis to market the experimental blood clot preventative semuloparin sodium. In briefing papers prepared for the 20 June meeting where the agency's independent Oncologic Drugs Advisory Committee will issue its advice on Sanofi's new drug application, it offered a significantly different interpretation of trial results than does the company.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC017784

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel